The MEA prostate cancer nuclear medicine market is expected to grow from US$ 35.66 million in 2022 to US$ 62.49 million by 2028; it is estimated to grow at a CAGR of 9.8% from 2022 to 2028.
Prostate cancer is a prevalent male malignancy that remains a major health issue. In the clinical care of patients, imaging is critical. Prostate cancer imaging provides precise disease characterization through synthesizing anatomic, functional, and molecular imaging information. Prostate cancer detection has increased due to advances in imaging technologies, such as magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT). Lesion detection and local staging have improved due to MRI. Diffusion-weighted MRI, MR spectroscopy, and dynamic contrast-enhanced MRI are among the MRI techniques used to assess function. Conventional imaging options, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, are used for prostate cancer patients to detect organ-confined or metastatic disease for staging and prognosis. However, the use of imaging for assessing tumor grade, staging, finding minimal metastatic disease, and separating fatal from a nonlethal disease needs to be improved. Hybrid imaging approaches for diagnosis use complementary structural and morphological data to improve imaging resolution and sensitivity. For instance, the FDA approved a complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 to identify PSMA-positive lesions. After radiolabeling, this imaging agent may be used to identify PSMA-positive lesions in adult patients with mCRPC through a positron emission tomography scan.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA prostate cancer nuclear medicine market. The MEA prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
MEA Prostate cancer nuclear medicine Market Segmentation
The MEA prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the MEA prostate cancer nuclear medicine market is divided into PET and SPECT. The PET dominated the MEA prostate cancer nuclear medicine market in 2022. Based on PET product, the MEA prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the MEA prostate cancer nuclear medicine market in 2022. Based on end user, the MEA prostate cancer nuclear medicine market is categorized into hospitals, clinics, and others. The hospitals segment dominated the MEA prostate cancer nuclear medicine market in 2022. Based on country, the MEA prostate cancer nuclear medicine market is segmented into Saudi Arabia, UAE, South Africa, and the rest of the MEA. The Saudi Arabia segment dominated the MEA prostate cancer nuclear medicine market in 2022.
ImaginAb; Curium; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the MEA prostate cancer nuclear medicine market.